There are moments in the journey of each society when a product enters the bloodstream of culture and changes the rules of desirability through aspirations. Fair & Lovely did it with skin tone in India. Less costlier versions of Ozempic may do it with body weight.

India’s arranged marriage market has always been brutally efficient in ranking human worth. Height, skin colour, caste, salary, family background – everything is indexed, filtered and negotiated. And somewhere in that spreadsheet of expectations, ‘slim’ has remained a constant, especially for women. Until now, weight was at least partially insulated by the language of health, genetics, or ‘after marriage it will improve’. It was a soft disqualification, not always a permanent one.

Ozempic, and drugs like it, threaten to harden that softness into something far more unforgiving. Because for the first time, weight loss is being reframed as a purchasable outcome. This is what makes the shift dangerous in a country where millions of biodatas already list “fair” and “homely”, the arrival of a pharmaceutical shortcut transforms “slim” from a preference into an expectation. The logic becomes insidious in its simplicity: if weight loss is accessible, then being overweight is no longer a circumstance but it is a choice. And in a market that penalises deviation, choice becomes culpability.

You can already see the early signs. Stories of individuals using semaglutide-based drugs before........

© Eurasia Review